85 related articles for article (PubMed ID: 37938348)
21. Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.
Gray JE; Han JY; Telaranta-Keerie A; Huang X; Kohlmann A; Hodge R; Rukazenkov Y; Chmielecki J; Espenschied CR; Lefterova M; Wu YL; Ramalingam SS; Barrett JC; Odegaard JI
J Mol Diagn; 2024 Jan; 26(1):73-84. PubMed ID: 37981090
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in non-small cell lung cancer cells: From the insight into the gene transcriptional level.
Yin R; Gao J; Liu Y
Chem Biol Drug Des; 2024 Jan; 103(1):e14435. PubMed ID: 38230781
[TBL] [Abstract][Full Text] [Related]
24. A Path to Persistence after EGFR Inhibition.
Rumde PH; Burns TF
Cancer Res; 2024 Apr; 84(8):1188-1190. PubMed ID: 38616658
[TBL] [Abstract][Full Text] [Related]
25. Combination of Osimertinib and Olaparib Therapy to Treat Non-Small Cell Lung Cancer and High-Grade Serous Ovarian Carcinoma: A Case Report.
Lin J; Welch S; Sanatani M; Ramadan S
Curr Oncol; 2024 Jan; 31(1):558-565. PubMed ID: 38275832
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports.
Bao LC; Padovan A; Boscolo Bragadin A; Calvetti L; Guarneri V; Bonanno L; Indraccolo S
Front Oncol; 2024; 14():1363069. PubMed ID: 38529368
[TBL] [Abstract][Full Text] [Related]
27. Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient.
Pons-Tostivint E; Hulo P; Sagan C; Papazyan T; Herbreteau G; Denis M
Respir Med Res; 2024 May; 86():101116. PubMed ID: 38843599
[No Abstract] [Full Text] [Related]
28. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.
de Jager VD; Stigt JA; Niemantsverdriet M; Ter Elst A; van der Wekken AJ
NPJ Precis Oncol; 2024 May; 8(1):113. PubMed ID: 38778166
[TBL] [Abstract][Full Text] [Related]
29. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.
Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140788
[TBL] [Abstract][Full Text] [Related]
30. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
31. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
[TBL] [Abstract][Full Text] [Related]
32. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
Leonetti A; Verzè M; Minari R; Perrone F; Gnetti L; Bordi P; Pluchino M; Nizzoli R; Azzoni C; Bottarelli L; Lagrasta CAM; Mazzaschi G; Buti S; Gasparro D; Cosenza A; Ferri L; Majori M; De Filippo M; Ampollini L; La Monica S; Alfieri R; Silini EM; Tiseo M
Br J Cancer; 2024 Jan; 130(1):135-142. PubMed ID: 37938348
[TBL] [Abstract][Full Text] [Related]
33. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
34. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
35. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB
J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383
[TBL] [Abstract][Full Text] [Related]
36. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
